JNCI Monographs · 2001 · 93 citations · 19 references
MedicineEndocrinologyOncologyBreast OncologyCancer Symptom ManagementWomen's HealthAdjuvant TherapyHormonal TherapyMenopause CareMenopause Hormone TherapyMenopause ManagementSide EffectsAdjuvant Hormonal TherapyContralateral Breast Cancer RiskDisease-free Survival AssessmentHormone Therapy Side EffectsSelf-report QuestionnairesSexual FunctioningSurvival RatesTherapy-induced Menopausal Symptoms
This article reviews the symptoms and everyday problems associated with tamoxifen adjuvant therapy and their impact on patients' quality of life. In addition, the purported toxic effects of tamoxifen therapy (e.g., premature menopause, weight gain, and depression) are discussed, and data are presented that refute claims of the toxicity of tamoxifen therapy. From randomized controlled trials of adjuvant therapy, we know that tamoxifen therapy increases the rate of hot flashes, night sweats, and vaginal discharge; however, in observational studies these symptoms do not have a statistically significant impact on patients' quality of life as measured by standardized, self-report questionnaires. The Breast Cancer Prevention Trial found no evidence of excessive rates of depression or clinically significant differences in sexual functioning between women receiving placebo and those receiving tamoxifen therapy. Although several serious medical risks from tamoxifen therapy exist (e.g., uterine cancer, blood clots, stroke, and cataracts), there are additional benefits from tamoxifen therapy in addition to an increase in disease-free survival rates and overall survival rates, including a decrease in contralateral breast cancer and fractures. Ultimately, the decision to receive tamoxifen therapy is a personal choice for each woman to make on the basis of the evidence of tamoxifen therapy's benefits and risks, along with her own motivation to receive therapy. When the benefits of such therapy are small, some women may choose to avoid treatment, but others may wish to try therapy to determine whether possible side effects are relevant. For women in whom the absolute survival benefits are large, there may be less difficulty in making this decision.
19
Bernard Fisher, Joseph P. Costantino, D. Lawrence Wickerham et al. · JNCI Journal of the National Cancer Institute · 1998 · 5.5K citations · Full text
B. Fisher, Joseph P. Costantino, Carol Redmond et al. · JNCI Journal of the National Cancer Institute · 1994 · 1.3K citations
Medicine, Gynecology, Oncology +14
Risk of Menopause During the First Year After Breast Cancer Diagnosis
Pamela J. Goodwin, Marguerite Ennis, Kathleen I. Pritchard et al. · Journal of Clinical Oncology · 1999 · 604 citations
Medicine, Endocrinology, Oncology +17